# Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)

> **NCT01006538** · PHASE4 · COMPLETED · sponsor: **King's College Hospital NHS Trust** · enrollment: 363 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DEVICE:** Epimacular Brachytherapy
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01006538
- **Lead sponsor:** King's College Hospital NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2015-03
- **Final completion:** 2016-12
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006538, "Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01006538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*